6.19
Foghorn Therapeutics Inc stock is traded at $6.19, with a volume of 102.16K.
It is down -4.33% in the last 24 hours and up +27.10% over the past month.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
See More
Previous Close:
$6.47
Open:
$6.42
24h Volume:
102.16K
Relative Volume:
0.80
Market Cap:
$345.04M
Revenue:
$34.16M
Net Income/Loss:
$-98.43M
P/E Ratio:
-2.6453
EPS:
-2.34
Net Cash Flow:
$-119.33M
1W Performance:
+1.48%
1M Performance:
+27.10%
6M Performance:
+52.46%
1Y Performance:
-0.96%
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Name
Foghorn Therapeutics Inc
Sector
Industry
Phone
617-586-3100
Address
500 TECHNOLOGY SQUARE, CAMBRIDGE
Compare FHTX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
FHTX
Foghorn Therapeutics Inc
|
6.19 | 353.40M | 34.16M | -98.43M | -119.33M | -2.34 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
Jan-30-25 | Initiated | B. Riley Securities | Buy |
Sep-03-24 | Initiated | Jefferies | Buy |
Aug-19-24 | Initiated | Evercore ISI | Outperform |
Mar-28-23 | Initiated | BofA Securities | Buy |
Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
Nov-22-21 | Initiated | H.C. Wainwright | Buy |
Nov-17-20 | Initiated | Cowen | Outperform |
Nov-17-20 | Initiated | Goldman | Buy |
Nov-17-20 | Initiated | Morgan Stanley | Overweight |
Nov-17-20 | Initiated | Wedbush | Outperform |
View All
Foghorn Therapeutics Inc Stock (FHTX) Latest News
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Foghorn Therapeutics Inc. Stock Analysis and ForecastOutstanding risk-reward balance - Autocar Professional
Trading (FHTX) With Integrated Risk Controls - news.stocktradersdaily.com
What analysts say about Foghorn Therapeutics Inc. stockAccelerated capital growth - jammulinksnews.com
What drives Foghorn Therapeutics Inc. stock pricePhenomenal capital appreciation - jammulinksnews.com
Is Foghorn Therapeutics Inc. a good long term investmentFree Stock Market Trend Analysis - jammulinksnews.com
Foghorn Therapeutics (NASDAQ:FHTX) Stock Price Down 0.5% – What’s Next? - Defense World
Why Foghorn Therapeutics Inc. stock attracts strong analyst attentionTriple Return With Stability - Newser
SAIL Stock Analysis and ForecastFree Trading Psychology Coaching - Jammu Links News
What analysts say about Leonardo DRS Inc. stockMarket-beating performance - Jammu Links News
What makes Foghorn Therapeutics Inc. stock price move sharplyHigh Potential Safe Trades - Newser
How Foghorn Therapeutics Inc. stock performs during market volatilityConsistent Win Signals - Newser
(FHTX) Trading Report - news.stocktradersdaily.com
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares May Have Run Too Fast Too Soon - simplywall.st
(FHTX) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
112-employee biotech leaves Cambridge HQ for Watertown - The Business Journals
Foghorn Therapeutics Signs New Lease Agreement - TipRanks
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Exchange Traded Concepts LLC Grows Holdings in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
When the Price of (FHTX) Talks, People Listen - news.stocktradersdaily.com
Foghorn Therapeutics Holds Successful Annual Meeting - TipRanks
Bank of America Corp DE Has $149,000 Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Soft Tissue Sarcoma Pipeline 2025: MOA, ROA, FDA-Approved Drugs, And Clinical Trial Progress Assessment By Delveinsight Oncotherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma - MENAFN.com
Soft Tissue Sarcoma Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | OncoTherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma - Barchart.com
Trend Tracker for (FHTX) - news.stocktradersdaily.com
Millennium Management LLC Raises Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Acquired by Wellington Management Group LLP - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives $12.13 Consensus Target Price from Analysts - Defense World
BNP Paribas Financial Markets Makes New $61,000 Investment in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Northern Trust Corp Purchases 2,873 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Position Increased by D. E. Shaw & Co. Inc. - Defense World
Lazard Asset Management LLC Acquires New Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics Inc Stock (FHTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):